Cardiovascular diseases (CVD) are considered a major threat to global health. CVD biomarkers in blood are important indicators for CVD, being currently analyzed in specialized laboratories through expensive and time-consuming procedures (several hours). Therefore, for the rapid detection of biomarkers in undiluted plasma, we developed a new multiplexed and portable diagnostic system, CardioSense, based on a proprietary surface plasmon resonance (SPR) technology recently developed by us. For this, we also developed a biosensor for multiplexed SPR measurements, with increased sensitivity and robust to non-specific binding in undiluted plasma, as well as a portable and low-cost centrifugation system for rapid separation of plasma from blood. CVD biomarkers (B-natriuretic peptide, C-reactive protein, cardiac troponin I and myoglobin) are simultaneously detected by sensitive angle resolved SPR measurements in very low volumes of undiluted plasma (~10 μl). The novel system allows biomarker levels detection in minutes, and is cost effective, compatible with mass-production, and could be tailored to other biomarkers with minimal technology change. After testing and validation in clinical trials, the developed point-of-care device is envisaged to be used for rapid diagnosis (of CVD, and other diseases with known blood markers) in point of needs in hospitals (emergency departments).
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.